Celgene Continues Active January With $9B Juno Acquisition
Law360, New York (January 22, 2018, 8:49 AM EST) -- Celgene has agreed to buy rival biotechnology business Juno Therapeutics for around $9 billion, the companies said Monday, marking the second multibillion-dollar acquisition made by Celgene this month.
Under the terms of the transaction, Summit, New Jersey-based Celgene Corp. will acquire Seattle-headquartered Juno Therapeutics Inc. for $87 per share in cash. The deal, which was rumored last week, has been approved by the boards of directors for both companies.
Juno is focused on developing immunotherapies to treat cancer. The company has several product candidates that it says have shown “compelling clinical responses” in treating refractory leukemia and lymphoma.
"The acquisition of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!